Top Page
Global Health Limited
(Sydney:GLH)
Global Health Limited (GLH) vs. iShares MSCI Australia ETF (EWA)
Global Health Limited Business Overview & Revenue Model
Global Health Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.67M | 8.67M | 8.12M | 7.82M | 6.54M | 7.03M |
| Gross Profit | 2.10M | 2.10M | -689.94K | -2.18M | -664.00K | 812.71K |
| EBITDA | -792.62K | -793.08K | -1.22M | -7.19M | -1.69M | 57.05K |
| Net Income | -866.88K | -866.63K | -1.31M | -8.05M | -2.05M | -488.00K |
Balance Sheet | ||||||
| Total Assets | 2.84M | 2.84M | 3.08M | 3.12M | 11.03M | 9.04M |
| Cash, Cash Equivalents and Short-Term Investments | 1.38M | 1.38M | 2.07M | 2.24M | 6.38M | 4.84M |
| Total Debt | 1.46M | 1.46M | 1.03M | 44.94K | 141.83K | 304.11K |
| Total Liabilities | 6.58M | 6.58M | 5.98M | 4.74M | 4.95M | 5.00M |
| Stockholders Equity | -3.73M | -3.73M | -2.90M | -1.62M | 6.09M | 4.04M |
Cash Flow | ||||||
| Free Cash Flow | -706.63K | -706.63K | -1.15M | -4.36M | -2.08M | 675.18K |
| Operating Cash Flow | -706.63K | -706.63K | -1.13M | -3.46M | -1.18M | 1.37M |
| Investing Cash Flow | 5.00K | 5.00K | -17.48K | -902.77K | -778.93K | -428.74K |
| Financing Cash Flow | 98.20K | -10.70K | 982.56K | 240.86K | 3.50M | 3.23M |
Global Health Limited Technical Analysis
Global Health Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$42.73M | ― | -81.30% | ― | -36.68% | 79.41% | |
| ― | AU$10.24M | ― | ― | ― | -40.05% | -49.57% | |
| ― | AU$5.87M | -6.71 | ― | ― | -9.90% | 34.07% | |
| ― | AU$6.05M | ― | ― | ― | -67.78% | 37.66% | |
| ― | AU$14.63M | -5.00 | ― | ― | 241.34% | 44.19% | |
| ― | €4.23M | ― | -29.86% | ― | ― | 80.00% |
Global Health Limited Corporate Events
Global Health Limited has announced its Annual General Meeting (AGM) scheduled for 25 November 2025, encouraging shareholders to participate and submit proxy votes in advance. The company has adapted to new legislative requirements by offering electronic access to meeting documents and updates, reflecting its commitment to modern communication practices and stakeholder engagement.
Global Health Limited has announced the procedures for appointing proxies and voting at their upcoming Annual General Meeting scheduled for November 25, 2025. The announcement details the steps for shareholders to appoint proxies, vote on resolutions, and attend the meeting, emphasizing the importance of timely submission of proxy forms to ensure participation in key company decisions. This meeting will address significant resolutions, including the adoption of the remuneration report, re-election of a director, ratification of the company’s auditors, and approval of a 10% placement capacity, which could impact the company’s governance and financial strategies.
Global Health Limited has announced its Annual General Meeting (AGM) scheduled for November 25, 2025, in Melbourne. The meeting will cover the company’s financial statements, the adoption of the remuneration report, the re-election of director Steven Pynt, the ratification of PKF Melbourne Audit and Assurance Pty Ltd as company auditors, and the approval of a 10% placement capacity under ASX Listing Rule 7.1A. These resolutions are crucial for the company’s governance and operational strategy, impacting shareholder decisions and the company’s future financial and strategic direction.
Global Health Limited announced the cessation of 150,000 performance rights due to unmet conditions, effective October 17, 2025. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s operational performance and strategic direction.
Global Health Limited has announced the issuance of 710,000 performance rights under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market competitiveness.
Global Health Limited announced the cessation of 40,000 performance rights due to unmet conditions, effective September 30, 2025. This development may impact the company’s capital structure and could have implications for stakeholders, reflecting on the company’s operational adjustments and strategic focus.
Global Health Limited has announced the quotation of 116,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of an employee incentive scheme. This move is expected to enhance the company’s market presence and provide additional liquidity, potentially benefiting stakeholders by aligning employee interests with company performance.
Global Health Limited has announced a strategic partnership with SafeWork Health, marking its entry into the workplace health sector. This collaboration leverages Global Health’s SaaS ecosystem to enhance pre-employment health screenings, a growing market due to mandated compliance under Work Health and Safety legislation. The partnership positions Global Health to capture recurring revenue opportunities in a high-growth market segment, reinforcing its competitive market position and expanding its services beyond traditional healthcare. SafeWork Health will implement Global Health’s MasterCare+ Client Management System and other digital solutions to improve operational and regulatory processes in occupational health and safety.
Global Health Limited has issued a market update, clarifying that it is not offering shares and disclaims any responsibility for the accuracy or completeness of the information provided. The company advises potential investors to conduct their own research and seek professional advice before acquiring shares. This announcement highlights the company’s cautious approach to investor relations and emphasizes the risks and uncertainties associated with forward-looking statements, potentially impacting investor confidence and market perception.
Australia’s healthcare system faces significant challenges with 70% of its $240 billion expenditure dedicated to managing lifelong conditions. In the 2022-23 financial year, $82 billion was spent on chronic diseases, accounting for nearly half of all disease-related spending. The aging population is expected to grow, with older Australians projected to comprise 20.7% of the population by 2066. In 2022, 61% of Australians were living with at least one long-term health condition, highlighting the prevalence of chronic diseases. The National Framework for Chronic Conditions emphasizes the role of digital health in transitioning from institutionalized to home-based care, as chronic conditions remain the leading causes of disease burden.
Global Health Limited has released its corporate governance statement for the financial year ending June 30, 2025, which has been approved by the board and is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, demonstrating its commitment to transparency and accountability. This announcement reinforces Global Health Limited’s dedication to maintaining high governance standards, potentially strengthening its position in the market and reassuring stakeholders of its operational integrity.
Global Health Limited has released its Corporate Governance Statement for 2025, detailing its commitment to ethical standards, diversity, and board composition. The statement outlines the responsibilities of the board, the independence of non-executive directors, and the roles of the Chairman and CEO. It also covers corporate reporting, audit and remuneration committees, risk management, and shareholder communication. This comprehensive governance framework is designed to enhance transparency and accountability, potentially strengthening Global Health Limited’s position in the industry and reassuring stakeholders of its commitment to high governance standards.
Global Health Limited reported a decrease in revenue by 9.90% for the year ending June 30, 2025, with a consolidated loss of $866,632. The company did not declare any dividends for the current or previous financial periods, indicating ongoing financial challenges. The report also highlights a material uncertainty related to the company’s ability to continue as a going concern, which could impact its market positioning and stakeholder confidence.
Global Health Limited has signed a contract with Jarrah House to implement its SaaS applications, valued at $186,748.10, over an initial three-year term. This partnership will deploy the MasterCare+ Client Management System, including HotHealth Digital Front Door and ReferralNet Secure Messaging, to enhance AOD healthcare delivery at Jarrah House’s residential rehabilitation center in Sydney. The collaboration is expected to improve client data management and care provision, reflecting Global Health’s commitment to supporting multidisciplinary teams and service delivery in the AOD sector. The company continues to see growth in community-based platform contracts, with a revenue value exceeding $1.1 million this year and a strong pipeline forecasted through June 2026.
Global Health Limited reported a significant increase in new sales orders, with a 65% rise in sales for the financial year, primarily driven by its MasterCare Plus platform. The company is reducing its R&D expenditure as it nears completion of major projects and is incorporating AI to enhance productivity and reduce costs. The healthcare sector faces financial pressures, but Global Health aims to achieve profitability and positive cash flow by June 2026 through strategic cost control and AI adoption.